share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Truluck Joseph

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Adial Pharmaceuticals | 4：持股变动声明
美股SEC公告 ·  03/27 18:10

Moomoo AI 已提取核心信息

Joseph Truluck, the Chief Financial Officer of Adial Pharmaceuticals, Inc. (ADIL), was involved in a transaction on March 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The report also did not provide information on the number of shares held by Truluck after the transaction. Investors are advised to seek additional information to fully understand the impact of this event on their investment decisions.
Joseph Truluck, the Chief Financial Officer of Adial Pharmaceuticals, Inc. (ADIL), was involved in a transaction on March 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The report also did not provide information on the number of shares held by Truluck after the transaction. Investors are advised to seek additional information to fully understand the impact of this event on their investment decisions.
阿迪尔制药公司（ADIL）首席财务官约瑟夫·特鲁鲁克于2024年3月25日参与了一笔交易。公告中未披露该交易的具体细节，包括行动类型、状态、所涉股票数量、股票性质、交易价格和股票总价值。该报告也没有提供有关Truluck在交易后持有的股票数量的信息。建议投资者寻求更多信息，以充分了解这一事件对其投资决策的影响。
阿迪尔制药公司（ADIL）首席财务官约瑟夫·特鲁鲁克于2024年3月25日参与了一笔交易。公告中未披露该交易的具体细节，包括行动类型、状态、所涉股票数量、股票性质、交易价格和股票总价值。该报告也没有提供有关Truluck在交易后持有的股票数量的信息。建议投资者寻求更多信息，以充分了解这一事件对其投资决策的影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间